my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
08-03-2011: AstraZeneca and Galderma Pharma S.A. announced they have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide.
Under the terms of the agreement, Galderma will have exclusive access to a number of compounds from across AstraZeneca’s portfolio to develop in dermatological indications. Initial targets for collaboration have already been identified from disease areas as diverse as oncology, inflammation and central nervous system. These will be interrogated based on translational science and pre-clinical testing to determine the ones that will progress in the collaboration. The financial terms of the five-year agreement were not disclosed.
Watchlist
This is where you can add this news to your personal favourites
Drug shown to reverse radioiodine resistance in some advanced thyroid cancers
The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center. Published in the issue of the New England Jo ... more
Public-private collaboration launches to tackle antibiotic research
GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe that will see pharmaceutical and biotechnology companies working alongside public partners to tackle the rising threat from antibiotic resistance and address some of the key barrier ... more
Galapagos’ service companies, BioFocus and Argenta, announced they have entered into a multi-year collaboration agreement with AstraZeneca to find new compounds against key targets of interest to AstraZeneca’s research programs in respiratory and inflammatory diseases. Under the terms of th ... more
We discover new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. We also focus on getting the bes ... more
AstraZeneca is a leading global pharmaceutical company with an extensive product portfolio spanning six major therapeutic areas: gastrointestinal, cardiovascular, infection, neuroscience, oncology, and respiratory. In Canada, AstraZeneca employs approximately 1,050 employees and its headqua ... more
AstraZeneca and Galderma Pharma S.A. announced they have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for million ... more
Photocure divests Metvix to Galderma for EUR 51 million
Photocure ASA has entered into agreements with Galderma S.A., under which Galderma has purchased global rights, assets, and liabilities related to Metvix and Metvixia, as well as the exclusive right to develop new dermatology products based on Photocure's patented substance, MAL. Photocure ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
